Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

Exclusion Criteria22

• Other pathological types such as mucinous cancer, sex cord stromal cell tumor, etc.
• Presence of central nervous system (CNS) metastases or carcinomatous meningitis.
• Subjects with uncontrollable pleural, pericardial, or peritoneal effusion requiring repeated drainage.
• Subjects with other active malignancies within 3 years prior to randomization.
• Received systemic anti-tumor therapy within 2 weeks prior to randomization.
• Any prior treatments targeting the mechanism of tumor immunity.
• Major surgical , open biopsy or significant trauma within 4 weeks prior to randomization; or elective major surgical treatment required during the study.
• Active or potentially recurrent autoimmune disease.
• Subjects who require systemic treatment with glucocorticoid (\>10 mg/day of prednisone or equivalent glucocorticoid) or other immunosuppressive agents within 14 days prior to randomization.
• Receiving live vaccines within 4 weeks prior to randomization.
• Known primary or secondary immunodeficiencies, including testing positive for human immunodeficiency virus (HIV) antibodies.
• Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
• Known history of interstitial lung disease or non-infectious pneumonitis.
• Serious infections requiring hospitalization.
• Presence of active infection requiring systemic therapy.
• Subjects with active hepatitis B and active viral hepatitis C.
• Active or documented inflammatory bowel diseases, active diverticulitis.
• Subjects with clinically significant cardio-cerebrovascular disease.
• Unresolved toxicities from prior anticancer therapy.
• History of severe hypersensitivity reactions to other mAbs.
• Pregnant or lactating women.
• Any condition that, in the opinion of the Investigator, may result in a risk when receiving the study drug.